This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Filter 379,188 trials Clear all
Filter by:

Efficacy of PRUcalopride in Critically Ill Patients With Paralytic ILeus

  • Status Recruiting
    Recruiting
  • Condition Paralytic Ileus, Critically Ill
    Paralytic Ileus, Critically Ill
  • Phase Phase 3
    Phase 3
INTERVENTION

Drug: Prucalopride, Drug: Placebo

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Prucalopride, Drug: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand

Brief Summary

Paralytic ileus is a common intestinal dysfunction in critically ill patients. There are still no established the effective medications except correcting the primary causes and prokinetics trial which limited in efficacy and potential adverse events.

AuTophagy Activation for Cardiomyopathy Due to Anthracycline tReatment (ATACAR)Trial

  • Status Recruiting
    Recruiting
  • Condition Lymphoma
    Lymphoma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Carvedilol, Drug: Lisinopril, Drug: Pravastatin, Drug: Spironolactone

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Carvedilol, Drug: Lisinopril, Drug: Pravastatin, Drug: Spironolactone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Brief Summary

Researchers are comparing two drug therapy plans to treat heart function changes after anthracycline-based treatment for lymphoma.

A Study of RC98 in Subjects With Advanced Malignant Solid Tumors

  • Status Recruiting
    Recruiting
  • Condition Solid Tumors
    Solid Tumors
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: RC98

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: RC98

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Tianjin Cancer Hospital, Tianjin, Tianjin, China

Brief Summary

This study will evaluate the safety, tolerability and pharmacokinetics of RC98 for injeciton in subjects with advanced malignant solid tumors.

Gum Arabic as Anti-oxidant, Anti-inflammatory and Fetal Hemoglobin Inducing Agent in Sickle Cell Anemia Patients

  • Status Recruiting
    Recruiting
  • Condition Sickle Cell Anemia in Children
    Sickle Cell Anemia in Children
  • Phase Phase 2 Phase 3
    Phase 2 Phase 3
INTERVENTION

Dietary Supplement: Acacia Senegal extract, Dietary Supplement: Pectin

Eligibility
  • Ages: 3 to 18 Years (Child, Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Dietary Supplement: Acacia Senegal extract, Dietary Supplement: Pectin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Military Hospital, Omdurman, Khartoum, Sudan

Brief Summary

To study the efficacy of Gum Arabic as an anti-oxidant, anti-inflammatory and Fetal Hemoglobin-inducing agent among Sickle Cell Disease children. Half of participants will receive Gum Arabic and the other half will receive placebo

Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen

  • Status Recruiting
    Recruiting
  • Condition Advanced Biliary Tract Tumors
    Advanced Biliary Tract Tumors
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Toripalimab injection combined with GEMOX

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Toripalimab injection combined with GEMOX

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Haijun Zhong, Zhenjiang, Hangzhou, China

Brief Summary

This is an open, single-arm, single-center, prospective phase II clinical study to evaluate the efficacy and safety of first-line tripletrumab combined with GEMOX chemotherapy in patients with advanced biliary tract tumors. Selected patients will receive the following treatment: Triplel monoclonal antibody (240mg, intravenous drip, d1, q3w);Combined with gemcitabine (1000mg/m2, intravenous drip, d1, d8, q3w) and oxaliplatin (100mg/m2, intravenous drip, d1, q3w) until the disease progresses or an intolerable adverse reaction occurs (the maximum treatment time is 2 years).

Efficacy and Safety of Flamboyant 200/12 Association in the Treatment of Adults With Severe Asthma

  • Status Not yet recruiting
    Not yet recruiting
  • Condition Asthma
    Asthma
  • Phase Phase 3
    Phase 3
INTERVENTION

Drug: Flamboyant 200/12, Drug: Budesonide / Formoterol 400/12, Other: Flamboyant 200/12 Placebo, Other: Budesonide / Formoterol 400/12 Placebo

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Flamboyant 200/12, Drug: Budesonide / Formoterol 400/12, Other: Flamboyant 200/12 Placebo, Other: Budesonide / Formoterol 400/12 Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of Flamboyant 200/12 association in adults with asthma.

Conditioning Electrical Stimulation to Improve Outcomes in Carpal Tunnel Syndrome

  • Status Recruiting
    Recruiting
  • Condition Carpal Tunnel Syndrome
    Carpal Tunnel Syndrome
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Procedure: Conditioning electrical stimulation, Procedure: Postoperative electrical stimulation, Procedure: No electrical stimulation

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Procedure: Conditioning electrical stimulation, Procedure: Postoperative electrical stimulation, Procedure: No electrical stimulation

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Alberta, Edmonton, Alberta, Canada

Brief Summary

Carpal tunnel syndrome is common, identified in 3% of the general population. Symptoms including numbness and pain are due to compression of the median nerve as it travels through a tunnel entering the wrist and can result in weakened grip strength and poor dexterity. Despite surgical release, nerve damage due to chronic compression often cannot be completely reversed, with resulting sensorimotor deficits. Postoperative electrical stimulation (ES) has been well-reported to improve nerve regeneration and is currently standard of practice at our institution. Investigators of this study have recently shown in an animal model that by changing the timing of the ES from postoperative to preoperative, this "conditioning" electrical stimulation (CES) significantly improves nerve regeneration. Patients with severe carpal tunnel syndrome will be identified in plastic surgery clinics. Patients who consent to participating will undergo baseline testing including nerve conduction studies, sensory evaluation, motor testing, and patient-reported outcomes. Participants will be randomized to three groups: i) CES, ii) postoperative ES, and iii) no ES. CES will be delivered in clinic by placing a percutaneous needle alongside the median nerve, and stimulation will be delivered for one hour, with patient comfort dictating the voltage of stimulation. At the completion of one hour, the needle will be removed, and a standard carpal tunnel release will be performed by their plastic surgeon 4-7 days later. Patients will the second cohort will undergo postoperative ES immediately following their carpal tunnel release, using the same stimulation parameters as CES. The third cohort will receive only carpal tunnel release without stimulation.In all patients, sensory and motor reinnervation, using the same testing modalities as preoperative assessment, will be evaluated at 3, 6, and 12 months post-operative.

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

  • Status Recruiting
    Recruiting
  • Condition Relapsed or Refractory Multiple Myeloma
    Relapsed or Refractory Multiple Myeloma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Carfilzomib, Drug: Dexamethasone, Drug: Pomalidomide

Eligibility
  • Ages: 18 to 99 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Carfilzomib, Drug: Dexamethasone, Drug: Pomalidomide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Research Site, Birmingham, Alabama, United States

Brief Summary

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone

Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema

  • Status Recruiting
    Recruiting
  • Condition Corneal Edema, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy...
    Corneal Edema, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy...
  • Phase Phase 1
    Phase 1
INTERVENTION

Combination Product: EO1404, Procedure: Endothelial brushing or Descemet stripping

Eligibility
  • Ages: 21 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Combination Product: EO1404, Procedure: Endothelial brushing or Descemet stripping

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Asociación Para Evitar la Ceguera en México, IAP, Hospital "Dr. Luis Sánchez Bulnes", Mexico City, Mexico

Brief Summary

Single center, phase 1 study to evaluate the safety and tolerability of EO1404 in subjects with corneal edema secondary to pseudophakic bullous keratopathy or Fuch's endothelial dystrophy.

LITT and Pembrolizumab in Recurrent Brain Metastasis

  • Status Recruiting
    Recruiting
  • Condition Classical Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymp...
    Classical Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymp...
  • Phase Phase 1
    Phase 1
INTERVENTION

Combination Product: LITT + Pembrolizumab

Eligibility
  • Ages: 18 to 100 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Combination Product: LITT + Pembrolizumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

McKnight Brain Institute of the University of Florida, Gainesville, Florida, United States

Brief Summary

This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis after prior stereotactic radiosurgery (SRS).